Evolution of treatment patterns and survival outcomes in non-metastatic rectal cancer: a 15-year real-world single-center analysis Authors: Jeong Yun Jang, Haesol Lim, Jiyeon Ko, Jeong Ha Lee, Yuwon Kim, Sang Ah Chi, Gyu Sang Yoo, Hee Chul Park, Nalee Kim, Yong Beom Cho, Jeong Il Yu Published: 2026 ABSTRACT AbstractBackgroundTreatment strategies for rectal adenocarcinoma have undergone substantial evolution, driven by advances in surgical techniques, radiotherapy, and systemic therapies. Nonetheless, longitudinal evidence on their real-world adoption and survival trends remains limited. This study investigated temporal trends in patient characteristics, treatment patterns, and outcomes over a 15-year period at a high-volume Korean tertiary center.MethodsWe retrospectively evaluated 6,314 patients with non-metastatic rectal adenocarcinoma who received curative-intent treatment between 2008 and 2022. The study period was divided into five consecutive 3-year intervals to facilitate temporal comparisons.ResultsThe mean age at diagnosis was 59.4 years, and 62.0% of patients were male. The proportion of clinical T4 tumors increased substantially, from 7.0% to 28.0%, whereas well-differentiated histology declined over time. Minimally invasive surgery rose from 44.5% to 91.0%, driven by the growing adoption of robotic techniques. Neoadjuvant radiotherapy replaced adjuvant radiotherapy as the predominant approach, and capecitabine-based regimens became the most frequent systemic therapy. Across the entire cohort, the 5-year survival rate was 87.6%, with overall survival showing steady improvement across study periods. Relative to the general population, the standardized mortality ratio declined from 5.57 in Period 1 to 3.33 in Period 5, reflecting a measurable reduction in excess mortality. Among patients with locally advanced disease, the highest five-year survival rate was 88.4% in those treated with neoadjuvant therapy followed by surgery.ConclusionsThese findings demonstrate substantial temporal changes in multidisciplinary rectal cancer management, with improved survival observed over time, supporting the continued refinement of multidisciplinary care strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16312-8.Keywords: Rectal cancer, Neoadjuvant therapy, Minimally invasive surgical procedures, Radiotherapy, Survival analysis Background Rectal cancer remains a significant global health burden and is among the common malignancies associated with cancer-related mortality [1, 2]. In Korea, colorectal cancer is the third most commonly diagnosed malignancy and accounts for 9.7% of cancer-related deaths in men and 12.2% in women, according to 2023 estimates [3]. Although nationwide screening initiatives for adults aged 50 years and older have facilitated earlier detection, the overall disease burden remains substantial, driven by population ageing, Westernized dietary patterns, and lifestyle changes [4, 5]. Over recent decades, the treatment of rectal cancer has evolved substantially. The introduction of total mesorectal excision in the late 1980s markedly improved locoregional control and established the foundation for modern surgical standards [6, 7]. Subsequently, randomized trials, including the Swedish Rectal Cancer Trial and the German Rectal Cancer Study Group’s pivotal study, established the efficacy of preoperative radiotherapy and concurrent chemoradiotherapy in reducing local recurrence and improving tumor downstaging, particularly in patients with locally advanced disease [8–10]. More recently, minimally invasive surgical techniques, supported by evidence from large multicenter trials, have further transformed operative practice, with favorable oncologic and functional outcomes [11]. In parallel, the therapeutic landscape has expanded to include novel systemic agents and advanced radiotherapy techniques, further diversifying treatment strategies [12, 13]. Despite these advancements, comprehensive real-world assessments of the extent to which such innovations have been incorporated into routine clinical practice remain limited. Accordingly, we evaluated temporal trends in clinical characteristics, treatment strategies, and survival outcomes over a 15-year period at a tertiary care center in Korea to characterize real-world practice and outcomes in rectal cancer. Methods Study population and design Patients were initially identified from the institutional electronic medical record database using the ICD-10 diagnosis code for rectal cancer, C20, between January 2008 and December 2022. The retrieved cases were subsequently reviewed and cross-checked with pathology reports and medical records to confirm rectal adenocarcinoma, non-metastatic status at diagnosis, and receipt of curative-intent treatment. Patients with distant metastasis at diagnosis or those managed with supportive care only were excluded from the analysis (Supplementary Fig. 1). To evaluate temporal trends in patient characteristics, treatment patterns, and clinical outcomes, the study period was divided into five consecutive intervals: Period 1, 2008–2010; Period 2, 2011–2013; Period 3, 2014–2016; Period 4, 2017–2019; and Period 5, 2020–2022. Data collection and variables Baseline characteristics included sex, age at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS). Disease-related variables included clinical T category, clinical N status, clinical stage group, histologic subtype, and tumor differentiation. Clinical T category was recorded as T1, T2, T3, or T4, and clinical N status was recorded as node-negative or node-positive based on available clinical information at diagnosis. For consistency across the study period, clinical stage groups were retrospectively harmonized as stages I, II, and III according to the 8th edition of the American Joint Committee on Cancer staging system using the recorded clinical T and N information [14]. Treatment-related variables were assessed based on the initial definitive treatment course after diagnosis and included receipt of radical resection of the primary tumor, systemic therapy including cytotoxic chemotherapy or targeted agents, and pelvic radiotherapy. The initial definitive treatment modality was classified according to the combination and sequence of therapies, including surgery alone, radiotherapy alone, systemic therapy alone, neoadjuvant chemoradiotherapy (nCRT) followed by surgery, neoadjuvant radiotherapy (nRT) followed by surgery, surgery followed by adjuvant therapy (AT), and concurrent chemoradiotherapy (CRT) alone. For patients who underwent surgery, detailed information was obtained regarding surgical approach, categorized as open, laparoscopic, or robotic, as well as the type of procedure performed and corresponding pathologic outcomes. For systemic therapy, data were collected on the specific agents administered and the dates of initiation and completion. Radiotherapy-related variables included the target organ, total prescribed dose, fractionation scheme, timing relative to other treatment modalities, and overall treatment duration. Overall survival was calculated from the date of diagnosis to the date of death from any cause, with patients censored at the last follow-up in March 2023. Statistical analysis Baseline characteristics were summarized using frequencies and percentages for categorical variables and means with standard deviations (SDs) or medians with interquartile ranges (IQRs) for continuous variables, as appropriate. Missing values in categorical variables were retained as separate categories in descriptive analyses to preserve transparency regarding temporal changes in data completeness across study periods but were excluded from P-value calculations. The chi-square test or Fisher’s exact test was used for overall comparisons of categorical variables across the five periods, and the Kruskal-Wallis test was used for continuous or count variables. For selected binary, ordinal, continuous, or count variables in Tables 1 and 2, P values for trend were calculated by modeling diagnosis period as an ordinal variable. Trend tests were not applied to nominal variables without inherent ordering. Table 1Patient characteristics and initial treatment by time periodCharacteristicsPeriod 12008–2010(n = 1,299)Period 22011–2013(n = 1,304)Period 32014–2016(n = 991)Period 42017–2019(n = 1,332)Period 52020–2022(n = 1,388)Total(n = 6,314)P valueP for trend Patient Characteristics Sex Male808 (62.2)851 (65.3)621 (62.7)808 (60.7)826 (59.5)3,914 (62.0)0.0290.016 Female491 (37.8)453 (34.7)370 (37.3)524 (39.3)562 (40.5)2,400 (38.0)Age, years58.2 ± 10.959.5 ± 11.560.7 ± 11.758.9 ± 12.060.1 ± 12.059.4 ± 11.7< 0.001< 0.001ECOG PS 0–1443 (34.1)793 (60.8)583 (58.8)797 (59.8)1,046 (75.4)3,662 (58.0)< 0.001< 0.001 2–48 (0.6)11 (0.8)15 (1.5)8 (0.6)17 (1.2)59 (0.9) NA848 (65.3)500 (38.3)393 (39.7)527 (39.6)325 (23.4)2,593 (41.1)Clinical T stage T185 (6.5)90 (6.9)104 (10.5)97 (7.3)102 (7.4)478 (7.6)< 0.001< 0.001 T2209 (16.1)172 (13.2)200 (20.2)298 (22.4)284 (20.5)1,163 (18.4) T3602 (46.3)574 (44.0)443 (44.7)496 (37.2)492 (35.5)2,607 (41.3) T491 (7.0)105 (8.1)213 (21.5)334 (25.1)388 (28.0)1,131 (17.9) NA312 (24.0)363 (27.8)31 (3.1)107 (8.0)122 (8.8)935 (14.8)Clinical N stage N0275 (21.2)279 (21.4)334 (33.7)520 (39.0)481 (34.7)1,889 (29.9)< 0.001< 0.001 N1718 (55.3)661 (50.7)626 (63.2)757 (56.8)845 (60.9)3,607 (57.1) NA306 (23.6)364 (27.9)31 (3.1)55 (4.1)62 (4.5)818 (13.0)Clinical stage Stage I191 (14.7)192 (14.7)252 (25.4)321 (24.1)300 (21.6)1,256 (19.9)<0.001<0.001 Stage II78 (6.0)85 (6.5)80 (8.1)143 (10.7)128 (9.2)514 (8.1) Stage III718 (55.3)661 (50.7)626 (63.2)757 (56.8)845 (60.9)3,607 (57.1) NA312 (24.0)366 (28.1)33 (3.3)111 (8.3)115 (8.3)937 (14.8)Histology Adenocarcinoma1,272 (97.9)1,279 (98.1)967 (97.6)1,291 (96.9)1,354 (97.6)6,163 (97.6)0.408– Mucinous carcinoma26 (2.0)23 (1.8)24 (2.4)36 (2.7)32 (2.3)141 (2.2) Others1 (0.1)2 (0.2)0 (0.0)5 (0.4)2 (0.1)10 (0.2)Differentiation WD406 (31.3)608 (46.6)448 (45.2)482 (36.2)353 (25.4)2,297 (36.4)< 0.001< 0.001 MD797 (61.4)621 (47.6)500 (50.5)785 (58.9)985 (71.0)3,688 (58.4) PD32 (2.5)39 (3.0)28 (2.8)41 (3.1)27 (2.0)167 (2.6) NA64 (4.9)36 (2.8)15 (1.5)24 (1.8)23 (1.7)162 (2.6) Initial Treatment Primary treatment Surgery alone503 (38.7)527 (40.4)391 (39.5)452 (33.9)431 (31.1)2,304 (36.5)< 0.001– nCRT + Surgery325 (25.0)352 (27.0)244 (24.6)337 (25.3)377 (27.2)1,635 (25.9) nRT + Surgery7 (0.5)50 (3.8)111 (11.2)212 (15.9)211 (15.2)591 (9.4) Surgery + AT402 (31.0)313 (24.0)187 (18.9)235 (17.6)218 (15.7)1,355 (21.5) CRT alone34 (2.6)38 (2.9)35 (3.5)50 (3.8)108 (7.8)265 (4.2) RT alone4 (0.3)12 (0.9)7 (0.7)19 (1.4)25 (1.8)67 (1.1) Systemic therapy24 (1.9)12 (0.9)16 (1.6)27 (2.0)18 (1.3)97 (1.5)Major surgery No47 (3.6)51 (3.9)44 (4.4)66 (5.0)108 (7.8)316 (5.0)< 0.001< 0.001 Yes1,252 (96.4)1,253 (96.1)947 (95.6)1,266 (95.1)1,280 (92.2)5,998 (95.0)Conventional chemotherapy No492 (37.9)572 (43.9)489 (49.3)614 (46.1)637 (45.9)2,804 (44.4)< 0.001< 0.001 Yes807 (62.1)732 (56.1)502 (50.7)718 (53.9)751 (54.1)3,510 (55.6)Targeted therapy No1,254 (96.5)1,237 (94.9)892 (90.0)1,171 (87.9)1,263 (91.0)5,817 (92.1)< 0.001< 0.001 Yes45 (3.5)67 (5.1)99 (10.0)161 (12.1)125 (9.0)497 (7.9)RT to pelvis No629 (48.4)637 (48.9)499 (50.4)598 (44.9)546 (39.3)2,909 (46.1)< 0.001< 0.001 Yes670 (51.6)667 (51.2)492 (49.6)734 (55.1)842 (60.7)3,405 (53.9)Values are presented as n (%) or mean ± SD, as appropriate. Percentages may not sum to 100% due to rounding. Missing values were retained as separate categories for descriptive purposes but excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods, whereas P values for trend were calculated only for binary, ordinal, and continuous variables with clinically meaningful ordering. Trend tests were not applied to nominal variables without inherent ordering. All P values should be interpreted cautiously because of multiple comparisonsSD Standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status, NA Not available, WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated, nCRT Neoadjuvant chemoradiotherapy, nRT Neoadjuvant radiotherapy, AT Adjuvant therapy, CRT Concurrent chemoradiotherapy, RT Radiotherapy Patient characteristics and initial treatment by time period Values are presented as n (%) or mean ± SD, as appropriate. Percentages may not sum to 100% due to rounding. Missing values were retained as separate categories for descriptive purposes but excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods, whereas P values for trend were calculated only for binary, ordinal, and continuous variables with clinically meaningful ordering. Trend tests were not applied to nominal variables without inherent ordering. All P values should be interpreted cautiously because of multiple comparisons SD Standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status, NA Not available, WD Well differentiated, MD Moderately differentiated, PD Poorly differentiated, nCRT Neoadjuvant chemoradiotherapy, nRT Neoadjuvant radiotherapy, AT Adjuvant therapy, CRT Concurrent chemoradiotherapy, RT Radiotherapy Table 2Surgical and pathologic characteristics by time period in patients undergoing radical resection for rectal cancerCharacteristicsPeriod 12008–2010(n = 1,252)Period 22011–2013(n = 1,253)Period 32014–2016(n = 947)Period 42017–2019(n = 1,266)Period 52020–2022(n = 1,280)Total(n = 5,998)P valueP for trendSurgical Characteristics Surgical approach Local excision70 (5.6)50 (4.0)39 (4.1)88 (7.0)55 (4.3)302 (5.0)< 0.001– Open surgery626 (50.0)259 (20.7)108 (11.4)109 (8.6)60 (4.7)1,162 (19.4) Laparoscopic539 (43.1)892 (71.2)685 (72.3)742 (58.6)744 (58.1)3,602 (60.1) Robotic17 (1.4)52 (4.2)115 (12.1)327 (25.8)421 (32.9)932 (15.5)Type of surgery TAE/TEM70 (5.6)50 (4.0)39 (4.1)88 (7.0)55 (4.3)302 (5.0)< 0.001– AR226 (18.1)251 (20.0)65 (6.9)40 (3.2)44 (3.4)626 (10.4) LAR873 (69.7)862 (68.8)668 (70.5)744 (58.8)639 (49.9)3,786 (63.1) uLAR29 (2.3)14 (1.1)74 (7.8)193 (15.2)318 (24.8)628 (10.5) APR41 (3.3)50 (4.0)39 (4.1)44 (3.5)41 (3.2)215 (3.6) ISR11 (0.9)18 (1.4)55 (5.8)151 (11.9)171 (13.4)406 (6.8) Hartmann procedure2 (0.2)8 (0.6)7 (0.7)6 (0.5)12 (0.9)35 (0.6)Pathologic Findings Lymphatic invasion No923 (73.7)856 (68.3)695 (73.4)1,001 (79.1)1,056 (82.5)4,531 (75.5)< 0.001< 0.001 Yes282 (22.5)267 (21.3)225 (23.8)249 (19.7)218 (17.0)1,241 (20.7) NA47 (3.8)130 (10.4)27 (2.9)16 (1.3)6 (0.5)226 (3.8)Venous invasion No996 (79.6)973 (77.7)742 (78.4)984 (77.7)1,015 (79.3)4,710 (78.5)< 0.001< 0.001 Yes198 (15.8)130 (10.4)89 (9.4)83 (6.6)96 (7.5)596 (9.9) NA58 (4.6)150 (12.0)116 (12.3)199 (15.7)169 (13.2)692 (11.5)Perineural invasion No1,097 (87.6)886 (70.7)606 (64.0)840 (66.4)919 (71.8)4,348 (72.5)< 0.001< 0.001 Yes100 (8.0)229 (18.3)315 (33.3)411 (32.5)355 (27.7)1,410 (23.5) NA55 (4.4)138 (11.0)26 (2.8)15 (1.2)6 (0.5)240 (4.0)Surgical margin status Negative1,200 (95.9)1,225 (97.8)919 (97.0)1,230 (97.2)1,243 (97.1)5,817 (97.0)0.1110.419 Positive27 (2.2)15 (1.2)26 (2.8)24 (2.0)30 (2.3)122 (2.0) NA25 (2.0)13 (1.0)2 (0.2)12 (1.0)7 (0.6)59 (1.0)No. of lymph nodes retrieved, median [IQR]14 [10–20]14 [12–20]15 [12–19]15 [12–20]16 [13–21]15 [12–20]< 0.001< 0.001Pathologic T stage (y)pT0140 (11.2)107 (8.5)81 (8.6)152 (12.0)127 (9.9)607 (10.1)< 0.0010.427 (y)pTis15 (1.2)17 (1.4)12 (1.3)13 (1.0)16 (1.3)73 (1.2) (y)pT1147 (11.7)184 (14.7)141 (14.9)190 (15.0)195 (15.2)857 (14.3) (y)pT2310 (24.8)313 (25.0)236 (24.9)308 (24.3)314 (24.5)1,481 (24.7) (y)pT3565 (45.1)570 (45.5)426 (45.0)504 (39.8)516 (40.3)2,581 (43.0) (y)pT475 (6.0)62 (5.0)51 (5.4)99 (7.8)112 (8.8)399 (6.7)Pathologic N stage (y)pN0715 (57.1)757 (60.4)616 (65.1)789 (62.3)791 (61.8)3,668 (61.2)0.0010.010 (y)pN1311 (24.8)299 (23.9)214 (22.6)255 (20.1)298 (23.3)1,377 (23.0) (y)pN2151 (12.1)146 (11.7)75 (7.9)132 (10.4)135 (10.6)639 (10.7) (y)pNx75 (6.0)51 (4.1)42 (4.4)90 (7.1)56 (4.4)314 (5.2)Values are presented as n (%) or median [IQR], as appropriate. Percentages may not sum to 100% due to rounding. Missing values were retained for descriptive purposes but excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods, whereas P values for trend were calculated only for ordered or binary variables. Trend tests were not applied to nominal variables. All P values should be interpreted cautiously because of multiple comparisonsTAE Transanal excision, TEM Transanal endoscopic microsurgery, AR Anterior resection, LAR Low anterior resection, uLAR Ultra-low anterior resection, APR Abdominoperineal resection, ISR Intersphincteric resection, NA Not available, IQR Interquartile range Surgical and pathologic characteristics by time period in patients undergoing radical resection for rectal cancer Values are presented as n (%) or median [IQR], as appropriate. Percentages may not sum to 100% due to rounding. Missing values were retained for descriptive purposes but excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods, whereas P values for trend were calculated only for ordered or binary variables. Trend tests were not applied to nominal variables. All P values should be interpreted cautiously because of multiple comparisons TAE Transanal excision, TEM Transanal endoscopic microsurgery, AR Anterior resection, LAR Low anterior resection, uLAR Ultra-low anterior resection, APR Abdominoperineal resection, ISR Intersphincteric resection, NA Not available, IQR Interquartile range Overall survival was estimated using the Kaplan–Meier method, and differences in survival across treatment groups were assessed using the log-rank test. To assess the association between diagnosis period and overall survival, multivariable Cox proportional hazards regression was performed. Because the proportional hazards assumption was not adequately satisfied when the entire follow-up period was used, follow-up was truncated at 36 months for the multivariable Cox regression analysis. This approach was used to improve model validity and to provide a more comparable follow-up window across diagnosis periods. The final multivariable model included diagnosis period, sex, age at diagnosis, clinical T stage, clinical N stage, histology, differentiation, and initial treatment modality. ECOG PS was not included in the final model because of substantial missingness. Missing values for clinical T stage, clinical N stage, and differentiation were retained as separate categories in the primary model to avoid excluding patients with incomplete clinical information. A complete-case model using the same covariates was additionally performed as a sensitivity analysis. To compare mortality in the study population with that of the general Korean population, standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) were calculated using age-specific mortality data obtained from the Korean Statistical Information Service, provided by Statistics Korea. The reference mortality rates were derived from the national mortality statistics table “Number of deaths and death rates by sex and 5-year age group,” using the 2015 Korean population mortality data as the reference. Expected deaths were estimated by applying the corresponding age-specific mortality rates from the reference population to the corresponding distribution of the study population. SMRs were calculated as the ratio of observed deaths to expected deaths. The 95% CIs for SMRs were calculated using an exact method when the number of observed deaths was 5 or fewer and Byar’s approximation when the number of observed deaths was greater than 5. Assumptions for the applied statistical methods were assessed prior to analysis, including expected cell frequencies for categorical comparisons before applying the chi-square test. For Cox proportional hazards regression, the proportional hazards assumption was evaluated using Schoenfeld residuals and graphical assessment. Multicollinearity was assessed using generalized variance inflation factors. All analyses were performed using R version 4.2.2 (R Development Core Team, Vienna, Austria). A P value < 0.05 was considered statistically significant. Results Patient characteristics and initial treatment patterns A total of 6,314 patients with rectal adenocarcinoma who underwent definitive treatment between 2008 and 2022 were included in the analysis. Table 1 presents the distribution of key baseline characteristics and initial treatment modalities across five predefined periods. The mean age at diagnosis was 59.4 years, and 62.0% of the patients were male. The proportion of patients with ECOG PS 0–1 increased from 34.1% in Period 1 to 75.4% in Period 5, despite considerable missing data in earlier periods. The proportion of patients with clinical T4 disease increased from 7.0% to 28.0% over the study period, whereas node-positive disease remained above 50% across all time intervals. The majority of tumors were adenocarcinomas, with mucinous histology observed in 2.2% of cases. Poorly differentiated tumors accounted for less than 3% of cases in all periods, whereas the proportion of well-differentiated tumors decreased from 46.6% in Period 2 to 25.4% in Period 5. Regarding initial treatment patterns, surgery alone remained the most common modality in all periods, although its use decreased from 40.4% in Period 2 to 31.1% in Period 5. The use of nRT or nCRT followed by surgery increased from 25.5% in Period 1 to 42.4% in Period 5. The proportion of patients receiving CRT alone also increased from 2.6% to 7.8%. The proportion of patients receiving pelvic radiotherapy increased to 60.7% in the final period. The use of targeted agents expanded from 3.5% in Period 1 to a peak of 12.1% in Period 4, before slightly declining to 9.0% in Period 5. In contrast, conventional chemotherapy remained stable at approximately 55% throughout the study period. Surgical trends and pathologic features Surgical approaches and pathologic findings are summarized in Table 2. Among the 5,998 patients who underwent radical resection, the use of open surgery markedly declined from 50.0% in Period 1 to 4.7% in Period 5, while laparoscopic surgery remained the predominant approach across all periods. Robotic surgery showed a steady increase, accounting for 32.9% in Period 5 (Fig. 1A). Temporal trends in surgical management of rectal adenocarcinoma, showing (a) the distribution of surgical approaches (local excision, open, laparoscopic, and robotic) and (b) the proportion of minimally invasive surgery (laparoscopic or robotic) compared The proportion of patients undergoing minimally invasive surgery (MIS), including laparoscopic and robotic approaches, increased from 44.5% in Period 1 to 91.0% in Period 5 (Fig. 1B). Low anterior resection (LAR) was the most commonly performed operation, while the use of ultra-low anterior resection (uLAR) and intersphincteric resection (ISR) gradually increased. The frequency of local excision remained below 8% across all periods. Among surgical cases, lymphatic and perineural invasion were identified in 20.7% and 23.5% of patients, respectively, and positive resection margins were observed in 2.0%. The median number of retrieved lymph nodes was 15 (IQR, 12–20). T3 was the most common pathologic T stage, and 33.7% of patients had node-positive disease. In subgroup analyses, surgical and pathologic characteristics were evaluated separately for patients who underwent upfront radical resection and those who received neoadjuvant therapy followed by surgery (Supplementary Tables 1 and 2). In the upfront group, laparoscopic surgery accounted for 67.8% overall, while robotic surgery increased from 0.7% in Period 1 to 26.8% in Period 5. In the neoadjuvant group, open surgery accounted for 71.4% of procedures in Period 1 and decreased to 6.3% in Period 5, whereas robotic surgery increased to 40.3% in Period 5. Sphincter-preserving procedures, particularly uLAR and ISR, were more frequently performed after neoadjuvant therapy than after upfront surgery, with rates of 16.3% and 13.0% versus 6.7% and 2.8%, respectively. Lymphatic invasion was identified in 26.6% of upfront cases and in 10.8% after neoadjuvant therapy, while venous invasion was present in 12.1% and 6.0%, respectively. The median number of retrieved lymph nodes was 16 in the upfront group and 13 in the neoadjuvant group. Notably, pathologic complete response, defined as ypT0, was achieved in 19.3% of patients after neoadjuvant therapy. Pathologic node-negative status was more frequent after neoadjuvant therapy than after upfront surgery, at 68.0% versus 57.4%. Systemic therapy utilization Systemic therapy was described according to the initial regimen administered after diagnosis, and the distribution is presented in Supplementary Table 3. Conventional chemotherapy was given to 55.6% of patients across the entire period. The 5-fluorouracil (5-FU) plus leucovorin regimen (FL) was the most commonly used regimen in Period 1, accounting for 59.6% of initially administered chemotherapy, but its use decreased to 3.5% in Period 5. In contrast, capecitabine-based regimens, including capecitabine monotherapy and capecitabine plus oxaliplatin, increased from 30.6% in Period 1 to 85.2% in Period 5 and became the predominant approach. Targeted agents were administered to 7.9% of patients, increasing from 3.5% in Period 1 to 12.1% in Period 4 and 9.0% in Period 5 (Supplementary Fig. 2). Bevacizumab was the most frequently used targeted agent, followed by cetuximab. Systemic agents were further analyzed according to whether they were used with concurrent chemoradiotherapy or as systemic therapy alone (Supplementary Tables 4 and 5). Among patients receiving concurrent chemoradiotherapy, FL was the predominant regimen in Period 1, accounting for 56.1%, but decreased to 3.7% by Period 5. Capecitabine monotherapy increased from 40.2% to 89.5% and became the predominant regimen. Among patients treated with systemic therapy alone, fluorouracil-based combination regimens, including fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and fluorouracil, leucovorin, and irinotecan (FOLFIRI), remained predominant and collectively accounted for 83.6% in Period 5. Radiotherapy utilization A total of 3,405 patients received pelvic radiotherapy and were included in the radiotherapy-specific analysis (Table 3). The mean age at radiotherapy was 58.4 years, and 77.5% had an ECOG PS of 0–1. Stage III disease accounted for 71.7% of cases, and nearly all patients received photon beam therapy (99.4%). Table 3Patient and treatment characteristics by time period among patients with rectal cancer receiving pelvic radiotherapyCharacteristicsPeriod 12008–2010(n = 670)Period 22011–2013(n = 667)Period 32014–2016(n = 492)Period 42017–2019(n = 734)Period 52020–2022(n = 842)Total(n = 3,405)P valueAge at RT, years57.2 ± 10.958.0 ± 11.159.3 ± 11.558.0 ± 11.859.3 ± 12.258.4 ± 11.60.002ECOG PS0–1379 (56.6)591 (88.6)400 (81.3)567 (77.2)703 (83.5)2,640 (77.5)< 0.0012–44 (0.6)6 (0.9)4 (0.8)3 (0.4)10 (1.2)27 (0.8)NA287 (42.8)70 (10.5)88 (17.9)164 (22.3)129 (15.3)738 (21.7)Clinical stageStage I54 (8.1)27 (4.0)43 (8.7)115 (15.7)100 (11.9)339 (10.0)< 0.001Stage II44 (6.6)45 (6.7)45 (9.1)85 (11.6)86 (10.2)305 (9.0)Stage III469 (70.0)482 (72.3)394 (80.1)491 (66.9)606 (72.0)2,442 (71.7)NA103 (15.4)113 (16.9)10 (2.0)43 (5.9)50 (5.9)319 (9.4)Aim of RTNeoadjuvant332 (49.6)402 (60.3)355 (72.2)549 (74.8)588 (69.8)2,226 (65.4)< 0.001Adjuvant268 (40.0)172 (25.8)70 (14.2)83 (11.3)79 (9.4)672 (19.7)Others70 (10.4)93 (13.9)67 (13.6)102 (13.9)175 (20.8)507 (14.9)RT technique2D12 (1.8)0 (0.0)0 (0.0)0 (0.0)0 (0.0)12 (0.4)< 0.0013D-CRT612 (91.3)558 (83.7)334 (67.9)391 (53.3)286 (34.0)2,181 (64.1)IMRT6 (0.8)8 (1.2)24 (4.9)90 (12.3)276 (32.8)404 (11.9)NA40 (6.0)101 (15.1)134 (27.2)253 (34.5)280 (33.3)808 (23.7)Beam typePhoton669 (99.9)667 (100.0)484 (98.4)725 (98.8)842 (100.0)3,387 (99.4)< 0.001Proton1 (0.1)0 (0.0)8 (1.6)9 (1.2)0 (0.0)18 (0.5)Total dose, median [IQR], GyNeoadjuvant44.0 [44.0–44.0]44.0 [44.0–50.4]50.4 [50.0–50.4]50.4 [50.4–54.0]50.4 [50.4–54.0]50.4 [44.0–54.0]< 0.001Adjuvant44.0 [44.0–44.0]44.0 [44.0–44.0]45.0 [45.0–50.4]45.0 [45.0–50.0]45.0 [45.0–50.0]44.0 [44.0–45.0]Values are presented as n (%), mean ± SD, or median [IQR], as appropriate. Percentages may not sum to 100% due to roundingMissing values were retained as separate categories for descriptive purposes but were excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods and should be interpreted cautiously because of multiple comparisonsRT Radiotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, 2D Two-dimensional radiotherapy, 3D-CRT Three-dimensional conformal radiotherapy, IMRT Intensity-modulated radiotherapy, IQR Interquartile range Patient and treatment characteristics by time period among patients with rectal cancer receiving pelvic radiotherapy Values are presented as n (%), mean ± SD, or median [IQR], as appropriate. Percentages may not sum to 100% due to rounding Missing values were retained as separate categories for descriptive purposes but were excluded from P-value calculations. P values indicate overall comparisons across diagnosis periods and should be interpreted cautiously because of multiple comparisons RT Radiotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, 2D Two-dimensional radiotherapy, 3D-CRT Three-dimensional conformal radiotherapy, IMRT Intensity-modulated radiotherapy, IQR Interquartile range With respect to treatment intent, adjuvant radiotherapy decreased from 40.0% in Period 1 to 9.4% in Period 5, whereas neoadjuvant radiotherapy increased from 49.6% to 69.8% and became the predominant approach after 2009 (Fig. 2A). Radiotherapy administered for other indications, including palliative treatment or definitive therapy without surgery, increased to 20.8% in the most recent period. Temporal trends in radiotherapy utilization, showing (a) the proportion of neoadjuvant versus adjuvant radiotherapy and (b) the distribution of radiotherapy techniques (2D, 3D conformal radiotherapy, and intensity-modulated radiotherapy). a shows neoadjuvant and adjuvant radiotherapy. b shows radiotherapy techniques among all patients who received radiotherapy, excluding those with missing technique data Regarding radiotherapy techniques, among patients with available technique information, three-dimensional conformal radiotherapy (3D-CRT) accounted for more than 97% of cases in the first two periods but decreased to 50.9% in Period 5, whereas intensity-modulated radiotherapy (IMRT) increased from 1.0% to 49.1%, surpassing 3D-CRT by 2022 (Fig. 2B). The prescribed total dose for neoadjuvant radiotherapy increased from a median of 44.0 Gy in Period 1 to 50.4 Gy in later periods, whereas the median adjuvant dose ranged from 44.0 to 45.0 Gy across intervals. Survival outcomes The median overall survival for the entire cohort was not reached, and the 5-year overall survival rate was 87.6% (95% CI, 86.7–88.5). Adjusted 3-year overall survival curves were generated using a multivariable Cox model with follow-up truncated at 36 months, including diagnosis period, age at diagnosis, sex, clinical T category, clinical N status, histology, differentiation, and initial treatment modality (Fig. 3, Supplementary Table 6). A complete-case sensitivity analysis using the same covariates included 5,256 patients and 335 deaths. Key associations for age, clinical T4 disease, node-positive disease, poor differentiation, and initial treatment modality were similar to those in the primary missing-category model (Supplementary Fig. 3, Supplementary Table 7). Adjusted 3-year overall survival across diagnosis periods among patients with non-metastatic rectal adenocarcinoma (n = 6,314) Compared with the general Korean population, SMRs decreased from 5.57 in Period 1 to 3.33 in Period 5 (Supplementary Fig. 4, Supplementary Table 8). In age-stratified analyses, SMRs were highest among patients younger than 60 years (22.38–39.34), reflecting the very low expected background mortality at these ages, and were lower among those aged 60–69 years (4.28–10.11) and ≥ 70 years (1.84–4.47). Among 4,127 patients with locally advanced rectal cancer (LARC), defined as clinical N1 or clinical T3–4 disease, the 5-year overall survival rates were 88.4% after nCRT or nRT followed by surgery, 84.6% after upfront surgery, 60.4% after CRT or radiotherapy alone, and 44.5% after systemic therapy alone (Fig. 4A, P < 0.001). In a subgroup analysis of 2,824 patients who underwent surgery either after neoadjuvant therapy or as initial treatment followed by adjuvant therapy, nCRT or nRT followed by MIS showed higher survival than nCRT or nRT followed by open surgery (Fig. 4B). Among patients who received adjuvant therapy after upfront surgery, no significant difference in survival was observed between MIS and open surgery. Overall survival among patients with locally advanced rectal adenocarcinoma, compared by (a) primary treatment modality and (b) radiotherapy timing and surgical approach Discussion This study analyzed 15-year trends in multidisciplinary practice at a high-volume Korean tertiary center, focusing on curative treatment for non-metastatic rectal cancer. Although previous reports from Korea have addressed selected aspects of rectal cancer care, this study represents, to our knowledge, one of the most comprehensive longitudinal evaluations conducted to date [15, 16]. Comparable longitudinal efforts, such as the 16-year analysis by Wexner et al. in the United States, have similarly documented shifts in clinical practice [17]. Unlike that study, which included a steadily increasing proportion of patients with metastatic disease, our study was restricted to patients with non-metastatic disease treated with curative intent, allowing a focused evaluation of temporal shifts in patient profiles and treatment practices. In terms of baseline characteristics, the proportion of patients with clinical T4 disease increased substantially, whereas node-positive disease remained relatively stable. This divergence may reflect improved diagnostic accuracy, particularly owing to the broader adoption of high-resolution pelvic MRI for detecting extramural tumor extension [18]. At the same time, the proportion of patients with ECOG PS 0–1 increased markedly, likely reflecting improved patient selection for curative-intent therapy and more systematic clinical documentation in later years. Histologically, the decreasing proportion of well-differentiated tumors may reflect changes in the observed histologic profile over time. Taken together, these changes suggest that patients treated in more recent years presented with a higher measured disease burden. Furthermore, portions of the study period overlapped with major healthcare disruptions in Korea, including the 2015 MERS outbreak and the COVID-19 pandemic, which may have influenced referral patterns, healthcare utilization, and stage distribution during certain periods. These factors should be considered when interpreting longitudinal changes in treatment patterns and outcomes. Among the various domains of multidisciplinary care, surgical practice changed substantially, driven by the rapid adoption of MIS, which replaced open surgery as the predominant approach. In particular, the increased use of robotic surgery may reflect its potential advantages in pelvic dissection and functional preservation, as evaluated in randomized trials such as ROLARR, together with rapid institutional uptake [19]. Consistent with this shift, national data from Korea show a marked increase in laparoscopic surgery between 2013 and 2018, reaching adoption rates higher than those reported in Japan and several European countries [16, 20, 21]. Meanwhile, the rate of abdominoperineal resection remained consistently low at 3–4%, reflecting a longstanding institutional emphasis on organ preservation. In line with this approach, the use of uLAR increased substantially, likely reflecting evolving multimodality management strategies, including broader use of neoadjuvant therapy and advances in surgical techniques for low-lying tumors [22, 23]. Similar international trends have been reported, including a Chinese study showing an increase in sphincter-preserving surgery from 45.6% to 85.9% over two decades in tumors within five centimeters of the anal verge [24]. A Korean study of very low rectal cancer within three centimeters reported a preservation rate of 18.1%, while U.S. data showed an increase from 18.4% to 28.2% between 2006 and 2020, reflecting a global shift toward function-preserving treatment [25, 26]. Regarding systemic therapy, the replacement of infusional 5-FU with capecitabine-based regimens likely reflects a shift toward oral agents offering comparable efficacy and greater convenience, as also observed in international clinical practice [27]. The use of bevacizumab and cetuximab also increased during the study period, consistent with the incorporation of targeted agents into routine colorectal cancer care after pivotal clinical trials demonstrated survival benefits in metastatic disease [28, 29]. However, modest fluctuations in the later periods should be interpreted cautiously, as targeted agents were typically administered later in the disease course after recurrence or progression, and follow-up duration was shorter in more recently diagnosed patients. Radiotherapy practice shifted substantially, with neoadjuvant treatment emerging as the predominant approach and adjuvant therapy decreasing over time. The proportion receiving neoadjuvant radiotherapy with or without concurrent chemotherapy increased from 40.2% to 91.0%, whereas adjuvant therapy decreased from nearly 60% to 9.0%. This shift occurred more rapidly than in other countries, where neoadjuvant use increased only modestly, from 28.6% to 34.3% in the United States and from 58.2% to 62.6% in Spain [17, 30]. The relatively rapid transition in this cohort likely reflects system-level and institutional efforts to standardize care, including national quality assessments by the Health Insurance Review and Assessment Service since 2011, which incorporated indicators such as preoperative MRI utilization, use of nCRT, and adequacy of lymph node retrieval [31]. The introduction of additional reimbursement for multidisciplinary team consultations in 2014, together with society-level guidelines recommending nCRT for stage II–III disease, may have further promoted its adoption by incentivizing structured treatment planning [32]. During the same period, the use of IMRT in the neoadjuvant setting also increased, supported by evidence of its dosimetric advantages in reducing radiation exposure to adjacent organs while maintaining target coverage [33]. The LARC subgroup provided an additional perspective on temporal changes in multimodality treatment strategies among patients for whom treatment selection is particularly complex. LARC was defined pragmatically using clinical T and N stage to ensure consistent classification across the 15-year period, although this approach did not incorporate contemporary MRI-based risk features such as circumferential resection margin involvement, extramural venous invasion, or bulky nodal disease [34, 35]. Future studies with systematic MRI-based risk assessment would allow more refined classification and risk-stratified outcome interpretation. In addition, because treatment allocation in this subgroup likely reflected differences in tumor burden, operability, frailty, and comorbidity, survival comparisons across treatment groups should be interpreted descriptively rather than causally. Taken together, these evolving practices were accompanied by improved outcomes over time. Comparable trends have been documented in international settings, wherein the adoption of structured multidisciplinary care and standardized treatment algorithms coincided with favorable oncologic outcomes [17, 36]. In line with these findings, our SMR analysis showed a decline across study periods, suggesting improved survival relative to the general population. In interpreting age-specific SMRs, however, the very low background mortality among younger individuals should be considered. Key strengths of the present study include its large sample size, extended study period, and detailed characterization of multimodal treatment patterns at a high-volume tertiary center with extensive experience in rectal cancer management. Nevertheless, several limitations should be acknowledged. As a single-center retrospective analysis from a high-volume tertiary referral center, the findings may reflect institution-specific referral patterns, treatment preferences, and resource availability, and therefore may not fully represent nationwide clinical practice. In addition, missing data in ECOG PS and clinical staging variables, particularly in earlier periods, may have affected temporal comparisons and introduced residual bias related to changes in documentation and staging practices over time. Molecular and genetic data, including microsatellite instability and RAS/BRAF mutations, were not routinely available, limiting analyses stratified by tumor biology. Furthermore, detailed longitudinal information regarding second- or later-line treatment after recurrence was unavailable, precluding assessment of the potential contribution of evolving salvage therapies to long-term survival improvement. Survival comparisons across periods should also be interpreted cautiously because patients diagnosed in the most recent period had inherently shorter follow-up, which may limit assessment of long-term outcomes despite the use of Kaplan–Meier methods. Finally, emerging approaches such as total neoadjuvant therapy and short-course radiotherapy with delayed surgery warrant further investigation in real-world Korean populations, particularly with respect to compliance, toxicity, and long-term outcomes. Conclusions In conclusion, the treatment landscape for rectal cancer in Korea has transformed over the past 15 years, reflecting institutional efforts, evolving clinical guidelines, and technological advancements in multidisciplinary care. These temporal changes may have contributed to improvements in treatment quality and survival outcomes over time. Continued real-world evidence will remain important for refining treatment strategies and optimizing clinical practice. Supplementary Information Supplementary Material 1. Acknowledgements Not applicable. Abbreviations Two-dimensional radiotherapy Three-dimensional conformal radiotherapy 5-fluorouracil American Joint Committee on Cancer Abdominoperineal resection Anterior resection Adjuvant therapy Confidence interval Coronavirus disease 2019 Concurrent chemoradiotherapy Eastern Cooperative Oncology Group performance status Fluorouracil and leucovorin International Classification of Diseases,10th Revision Intensity-modulated radiotherapy Interquartile range Intersphincteric resection Low anterior resection Locally advanced rectal cancer Middle East respiratory syndrome Minimally invasive surgery Ministry of Science and ICT Neoadjuvant chemoradiotherapy Neoadjuvant radiotherapy Overall survival Poorly differentiated Standard deviation Standardized mortality ratio Transanal excision Transanal endoscopic microsurgery Ultra-low anterior resection Well differentiated Authors’ contributions Conceptualization: Jeong Yun Jang, Jeong Il Yu, Yong Beom Cho. Data curation: Haesol Lim, Jiyeon Ko, Jeong Ha Lee. Formal analysis: Yuwon Kim, Sang Ah Chi. Methodology: Jeong Yun Jang, Jeong Il Yu, Sang Ah Chi. Investigation: Haesol Lim, Jeong Ha Lee, Gyu Sang Yoo. Resources: Yong Beom Cho, Hee Chul Park, Nalee Kim. Software: Yuwon Kim. Supervision: Jeong Il Yu, Yong Beom Cho. Validation: Sang Ah Chi, Yuwon Kim. Visualization: Yuwon Kim, Jiyeon Ko. Writing – original draft: Jeong Yun Jang. Writing – review & editing: All authors. Funding This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2025-24683839) and the Bio&Medical Technology Development Program of the NRF funded by the MSIT (No. RS-2023-00222838). Data availability The datasets analyzed during the current study are not publicly available but could be shared by the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2023-11-128). The requirement for written informed consent was waived due to the retrospective design. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Yong Beom Cho, Email: yongbeom.cho@samsung.com. Jeong Il Yu, Email: jeongil.yu@samsung.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets analyzed during the current study are not publicly available but could be shared by the corresponding author on reasonable request.